Results 161 to 170 of about 18,393 (197)
Some of the next articles are maybe not open access.
Current Biology, 2022
Dopamine was first described by George Barger, James Ewens, and Henry Dale in 1910 as an epinephrine-like monoamine compound. Initially believed to be a mere precursor of norepinephrine, it was mostly ignored for the next four decades (Figure 1A). However, in the 1950s Kathleen Montagu showed that dopamine occurred in the brain by itself, and a series ...
Kauê Machado, Costa +1 more
openaire +2 more sources
Dopamine was first described by George Barger, James Ewens, and Henry Dale in 1910 as an epinephrine-like monoamine compound. Initially believed to be a mere precursor of norepinephrine, it was mostly ignored for the next four decades (Figure 1A). However, in the 1950s Kathleen Montagu showed that dopamine occurred in the brain by itself, and a series ...
Kauê Machado, Costa +1 more
openaire +2 more sources
Dopamine and non-dopamine psychoses
Psychopharmacology, 1984The time course of antipsychotic response following the initiation of an antipsychotic drug and functional dopamine receptor sensitivity were explored in a cohort of recently admitted psychotic (mood-incongruent) patients. The distribution of the latencies of antipsychotic response suggested at least two populations.
D L, Garver +4 more
openaire +2 more sources
Seminars in Neurology, 2001
Dopamine agonists provide an effective means of treating early, middle, and late stages of Parkinson's disease. This article outlines the advantages and disadvantages of dopamine agonists as compared with levodopa therapy. The features and costs of the four Food and Drug Administration-approved agonists (bromocriptine, pergolide, pramipexole, and ...
P, Tuite, B, Ebbitt
openaire +2 more sources
Dopamine agonists provide an effective means of treating early, middle, and late stages of Parkinson's disease. This article outlines the advantages and disadvantages of dopamine agonists as compared with levodopa therapy. The features and costs of the four Food and Drug Administration-approved agonists (bromocriptine, pergolide, pramipexole, and ...
P, Tuite, B, Ebbitt
openaire +2 more sources
Science, 1997
Ingrid Wickelgren's Special News Report “Getting the brain's attention” ([3 Oct., p. 35][1]) presents the views of those who question the current orthodoxy that dopamine acts in the nucleus accumbens as a key neurotransmitter underlying the behavioral effects of positive reinforcement or ...
J A, Gray, A M, Young, M H, Joseph
openaire +2 more sources
Ingrid Wickelgren's Special News Report “Getting the brain's attention” ([3 Oct., p. 35][1]) presents the views of those who question the current orthodoxy that dopamine acts in the nucleus accumbens as a key neurotransmitter underlying the behavioral effects of positive reinforcement or ...
J A, Gray, A M, Young, M H, Joseph
openaire +2 more sources